Tokyo, Japan, Japan · Est. 1921 · 47,000 employees
Otsuka Pharmaceutical is a diversified pharmaceutical company developing and marketing medications across psychiatry, oncology, and other therapeutic areas globally.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
By Phase
12 drugs in development
By Therapeutic Area
top 6
R&D Momentum
74/100
Pipeline Velocity
43/100
Trial Completion Rate
90/100
Pipeline Concentration
15/100
Pipeline Freshness
77/100
Strategic Signals
Activity
Last 14 days
Safety and Efficacy of Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder
Qualitative Interviews to Refine and Assess the Importance of Constructs, and Ensure the Readability of Patient, Carer, and Clinician Versions of the Treatment Preference in Myelodysplasia Questionnaire (TPMQ): pTPMQ, cTPMQ, and mTPMQ, Respectively
A Phase 2b, Multicenter, Open-label, Single-arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies Adults With Immunoglobulin A Nephropathy
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of Fixed Doses of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety Disorder
A Phase 3, Randomized, Open-label, Multicenter Trial to Evaluate the Efficacy, Safety, and Tolerability of 4-month and 6-month Quabodepistat-containing Regimens for Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial to Evaluate the Efficacy and Safety of EB-1020 Once Daily QD XR Capsules Administered Orally at Low or High Dose in Adults With Attention-deficit/Hyperactivity Disorder
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
A Phase 3, Multicenter, Open-label, Uncontrolled, Long-term Trial to Evaluate the Safety and Efficacy of Long-term Administration of EB-1020 Once Daily QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder
A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria
Details
Company Overview
—
Mkt Cap
$25.2M
Revenue
$2.2M
Cash
Therapeutic Focus
Recent SEC Filings
8-K
Pipeline
Regulatory
Abilify — ABILIFY
Application NDA021713 (NDA)
Mezofy — ABILIFY
Application NDA021713 (NDA)
Abilify — ABILIFY
Application NDA021866 (NDA)
Mezofy — ABILIFY
Application NDA021866 (NDA)
Abilify — ABILIFY
Application NDA021729 (NDA)
Mezofy — ABILIFY
Application NDA021729 (NDA)
Samsca — SAMSCA
Application NDA022275 (NDA)
Abilify — ABILIFY MAINTENA KIT
Application NDA202971 (NDA)
Mezofy — ABILIFY MAINTENA KIT
Application NDA202971 (NDA)
Rexulti — REXULTI
Application NDA205422 (NDA)
Abilify — ABILIFY MYCITE KIT
Application NDA207202 (NDA)
Mezofy — ABILIFY MYCITE KIT
Application NDA207202 (NDA)
Samsca — JYNARQUE
Application NDA204441 (NDA)
Abilify — ABILIFY ASIMTUFII
Application NDA217006 (NDA)
Mezofy — ABILIFY ASIMTUFII
Application NDA217006 (NDA)
Abilify — OPIPZA
Application NDA216655 (NDA)
Mezofy — OPIPZA
Application NDA216655 (NDA)
VOYXACT — VOYXACT
Application BLA761434 (BLA)
Abilify — MEZOFY
Application NDA211448 (NDA)
Mezofy — MEZOFY
Application NDA211448 (NDA)
8-K
Accession: 0001493152-26-047221
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)